
News|Articles|August 11, 2026
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
Fact checked by: Nick Ferreyros, Ron Panarotti
IRA reshapes Medicare drug costs: Part B negotiations loom, pharmacies adapt, and patients gain Part D caps—see impacts on oncology care and access.
Advertisement
Advertisement
The Inflation Reduction Act (IRA) has been law since 2022, but its most consequential provisions for oncology are only beginning to arrive. With the first negotiated drug prices now in effect, Part B drug negotiations on the horizon for 2028, and growing evidence of upstream effects on drug development investment, the IRA is no longer a future policy concern—it is an active one.
Related to this article

With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.

Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.

Pharmacists can help patients start buprenorphine for opioid use disorder by confirming when to take the first dose, whether another opioid continues during initiation, and who will manage symptoms and follow-up.

In older veterans, mRNA-1283 was associated with lower risks of medically attended COVID-19 and hospitalization than BNT162b2.

Pharmacists can use medication therapy management to screen for diabetes, educate patients about medication adherence and lifestyle modifications, and support early action.

In a phase 3 trial of children aged 6 to younger than 12 years, once-weekly semaglutide reduced BMI 16.2 percentage points more than placebo at 68 weeks.
Advertisement
Advertisement


